A health care attorney clarifies how amendments to the HIPAA Privacy Rule bear on the recruitment of clinical trials subjects.
On 14 August 2002, the U.S. Department of Health & Human Services approved final amendments to the so-called Privacy Rule, the privacy regulations issued by HHS in December 2000. With regard to research recruitment and the need for an authorization for disclosure of protected health information to third parties, the language in the preamble to the final amendments is intended to clarify the following: Although 45 CFR 164.512(i)(1)(ii) allows use or disclosure of protected health information for research preparatory activities, including recruitment, on the hospitals site, the protected health information may not be removed from the hospitals site by the researcher for such activities without the patients authorization or waiver, or without alteration thereof by the institutional review board (IRB).
When can researchers view protected information about patients? Under 45 CFR 164.512(i)(1)(ii), a hospital may permit researchers to view protected health information about its patients for purposes of the researcher preparing the research protocol and recruiting subjects provided that the researcher demonstrates, either in writing or orally, that
When can researchers record and remove protected information? The researcher may record and remove protected health information from the hospitals premises only if the hospital either waives or modifies authorization requirements (and appropriately documents this) or obtains an authorization from the patient. Alternatively, the researcher may remove de-identified information, or the hospital may disclose a limited data set to the researcher, provided the hospital and the researcher enter into a data use agreement relating to the limited data set.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.